Functionally Characterizing the Noncoding Genome of Metastatic Prostate Cancer to Identify Therapeutic Vulnerabilities

Abstract

Prostate cancer (PCa) is dependent on the androgen receptor (AR) at all stages of the disease. Standard of care treatment for advanced PCa focuses on inhibition of androgen signaling. Despiteinitial efficacy, resistance inevitably occurs. Notably, this state, termed metastatic castration resistant prostate cancer (mCRPC), remains dependent on AR signaling. Our groups have identified a set of 17,000 gained AR binding sites that characterize mCRPC. Our proposal aims to functionally characterize these important sites through a variety of approaches.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2023
Accession Number
AD1207388

Entities

People

  • Matthew L Freedman

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Cancer
  • Cell Line
  • Computer Programming
  • Genetics
  • Governments
  • Instructors
  • Medical Personnel
  • Neoplasms
  • Professional Development
  • Prostate Cancer
  • Statistical Analysis
  • Students
  • Training
  • Vulnerability

Fields of Study

  • Biology

Readers

  • Molecular and genetic basis of cancer.
  • Prostate Cancer Biology.